Oligonucleotide set for detecting apramycin-resistant bacteria, method for detecting apramycin-resistant bacteria, screening method for targeting apramycin administration, method for predicting susceptibility to apramycin administration, method for treating bacterial infections, and composition for treating bacterial infections.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- NAT AGRI & FOOD RES ORG
- Filing Date
- 2024-12-11
- Publication Date
- 2026-06-23
AI Technical Summary
【0012】 本発明によれば、高感度かつ特異的に、また、簡便かつ迅速に、試料中のアプラマイシン耐性細菌を検出可能なオリゴヌクレオチドセット、並びに、これを用いたアプラマイシン耐性細菌検出方法、アプラマイシン投与対象のスクリーニング方法、アプラマイシン投与に対する感受性予測方法、細菌感染症治療方法、及び細菌感染症治療用組成物を提供することが可能となる。
Smart Images
Figure 2026102248000006 
Figure 2026102248000007 
Figure 2026102248000008
Abstract
Claims
1. This is a set of oligonucleotides for detecting apramycin-resistant bacteria. Oligonucleotide primer 1 that hybridizes to 15 or more bases in the complementary sequence of the nucleotide sequence of sequence number 1, Oligonucleotide primer 2 hybridizes to 15 or more bases of the nucleotide sequence of sequence number 2, A set of oligonucleotides characterized by containing the following.
2. The oligonucleotide set according to claim 1, characterized in that the oligonucleotide primer 1 is an oligonucleotide containing 15 or more bases from the nucleotide sequence of SEQ ID NO:
1.
3. The oligonucleotide set according to claim 1, characterized in that the oligonucleotide primer 2 is an oligonucleotide containing 15 or more bases of the complementary sequence of the nucleotide sequence of SEQ ID NO:
2.
4. The oligonucleotide set according to claim 1, further comprising a labeled oligonucleotide probe that hybridizes to five or more bases of the nucleotide sequence of Sequence ID No. 3 or its complementary sequence.
5. The oligonucleotide set according to claim 4, characterized in that the oligonucleotide probe is a labeled oligonucleotide containing five or more bases from the nucleotide sequence of Sequence ID No. 3 or its complementary sequence.
6. This is a method for detecting apramycin-resistant bacteria in a sample. Using nucleic acids derived from the aforementioned sample as a template, Oligonucleotide primer 1 that hybridizes to 15 or more bases in the complementary sequence of the nucleotide sequence of sequence number 1, Oligonucleotide primer 2 hybridizes to 15 or more bases of the nucleotide sequence of sequence number 2, A method characterized by including an amplification step of performing nucleic acid amplification using an oligonucleotide set containing [a specific component].
7. This is a screening method for patients to receive apramycin. Using nucleic acids derived from samples collected from the subject as a template, Oligonucleotide primer 1 that hybridizes to 15 or more bases in the complementary sequence of the nucleotide sequence of sequence number 1, Oligonucleotide primer 2 hybridizes to 15 or more bases of the nucleotide sequence of sequence number 2, An amplification step in which nucleic acid amplification is performed using an oligonucleotide set containing, and A step of selecting subjects from whom no amplification product was detected in the amplification step to be administered apramycin. A method characterized by including
8. This is a method for predicting the sensitivity of a subject to apramycin administration. Using nucleic acids derived from samples collected from the subject as a template, Oligonucleotide primer 1 that hybridizes to 15 or more bases in the complementary sequence of the nucleotide sequence of sequence number 1, Oligonucleotide primer 2 hybridizes to 15 or more bases of the nucleotide sequence of sequence number 2, An amplification step in which nucleic acid amplification is performed using an oligonucleotide set containing, and A step in which a sample from which no amplification product was detected in the above amplification step is taken is to predict that the subject is susceptible to apramycin administration. A method characterized by including
9. This is a method of treating subjects suffering from bacterial infections by administering apramycin. Using nucleic acids derived from samples collected from the subject as a template, Oligonucleotide primer 1 that hybridizes to 15 or more bases in the complementary sequence of the nucleotide sequence of sequence number 1, Oligonucleotide primer 2 hybridizes to 15 or more bases of the nucleotide sequence of sequence number 2, An amplification step in which nucleic acid amplification is performed using an oligonucleotide set containing, and A step of administering apramycin to a sample from which no amplification product was detected in the amplification step described above. A method characterized by including
10. The method according to any one of claims 6 to 9, characterized in that the nucleic acid amplification is real-time PCR using the oligonucleotide set further comprising a labeled oligonucleotide probe that hybridizes to five or more bases of the nucleotide sequence of Sequence ID No. 3 or its complementary sequence.
11. This is an apramycin-containing composition for administration to subjects suffering from bacterial infections. A composition characterized by being used to amplify nucleic acids using an oligonucleotide set comprising an oligonucleotide primer 1 that hybridizes to 15 or more bases of the complementary sequence of the nucleotide sequence of SEQ ID NO: 1, and an oligonucleotide primer 2 that hybridizes to 15 or more bases of the nucleotide sequence of SEQ ID NO: 2, with nucleic acids derived from a sample taken from a subject as a template, and administering the sample from which no amplification product was detected to the subject from which the sample was taken.
12. The composition according to claim 11, characterized in that the nucleic acid amplification is real-time PCR using the oligonucleotide set further comprising a labeled oligonucleotide probe that hybridizes to five or more bases of the nucleotide sequence of Sequence ID No. 3 or its complementary sequence.